← Back to home

Eli Lilly Strikes Deal Worth Up to $1.5 Billion for Blood Cancer Biotech

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

Eli Lilly agreed on Nov. 16 to acquire Calytrix Bio in a cash deal worth as much as…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

4 confirmed facts and 3 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home
Eli Lilly Strikes Deal Worth Up to $1.5 Billion for Blood Cancer Biotech — NewsPlain